Advanced metastatic prostate cancer is a heterogeneous disease for which androgen deprivation therapy combined with and androgen receptor pathway inhibitor (ARPI) is the mainstay of treatment. All available therapies may be used in sequence after the ARPI. However, patient selection is key. There is a need to identify clinical or molecular predictive factors to assist in selecting systemic treatment sequences.
European urology focus. 2024 Aug 09 [Epub ahead of print]
Marco Gizzi, Emmanuel Seront, Bertrand Tombal, Julien Van Damme
Department of Medical Oncology, Grand Hôpital de Charleroi, Brussels, Belgium; Department of Medical Oncology, Cliniques Universitaires Saint Luc, Brussels, Belgium. Electronic address: ., Department of Medical Oncology, Cliniques Universitaires Saint Luc, Brussels, Belgium., Department of Urology, Cliniques Universitaires Saint Luc, Brussels, Belgium.